Theresa Mai-Hwang, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Theresa Mai-Hwang’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Medicaid work
$697 in 2021
Medicaid paid $697 for 16 billed services this clinician did in 2021, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (30+ min) | 16 | $697 |
| 2021 | 16 | 1 | 16 | $697 |
Drugs they prescribed that Part D paid
$2,993,393
Pharmacies billed $2,993,393 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,806) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
2,624 generic and 2,937 brand-name prescriptions · $2,993,393 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 645 | $653,312 | $1,013 |
| Ozempic | 462 | $649,040 | $1,405 |
| Rybelsus | 188 | $279,898 | $1,489 |
| Trulicity | 185 | $232,985 | $1,259 |
| Farxiga | 159 | $175,858 | $1,106 |
See all 65 drugs
| Jardiance | 645 | $653,312 | $1,013 |
| Ozempic | 462 | $649,040 | $1,405 |
| Rybelsus | 188 | $279,898 | $1,489 |
| Trulicity | 185 | $232,985 | $1,259 |
| Farxiga | 159 | $175,858 | $1,106 |
| Mounjaro | 64 | $84,284 | $1,317 |
| Fiasp Flextouch | 48 | $63,407 | $1,321 |
| Tresiba Flextouch U-100 | 107 | $59,051 | $552 |
| Invokana | 64 | $54,909 | $858 |
| Januvia | 55 | $54,291 | $987 |
| Tradjenta | 47 | $46,829 | $996 |
| Humalog Kwikpen U-100 | 118 | $37,127 | $315 |
| Kerendia | 36 | $36,770 | $1,021 |
| Teriparatide | 12 | $24,661 | $2,055 |
| Toujeo Solostar | 42 | $23,253 | $554 |
| Dapagliflozin | 40 | $22,277 | $557 |
| Toujeo Max Solostar | 15 | $21,021 | $1,401 |
| Xigduo Xr | 17 | $20,135 | $1,184 |
| Basaglar Kwikpen U-100 | 42 | $18,889 | $450 |
| Repaglinide | 371 | $17,580 | $47 |
| Tresiba Flextouch U-200 | 21 | $17,136 | $816 |
| Synjardy | 19 | $17,047 | $897 |
| Synjardy Xr | 16 | $16,995 | $1,062 |
| Humalog Kwikpen U-200 | 12 | $16,853 | $1,404 |
| Vascepa | 28 | $16,295 | $582 |
| Gvoke Hypopen 2-Pack | 25 | $15,688 | $628 |
| Insulin Lispro Kwikpen U-100 | 47 | $13,944 | $297 |
| Icosapent Ethyl | 28 | $13,443 | $480 |
| Nano 2nd Gen Pen Needle | 84 | $12,554 | $149 |
| Lantus Solostar | 100 | $11,082 | $111 |
| Cinacalcet | 20 | $10,634 | $532 |
| Repatha Sureclick | 12 | $10,127 | $844 |
| Novolog Flexpen | 29 | $8,060 | $278 |
| Praluent | 16 | $7,608 | $475 |
| Nateglinide | 73 | $7,348 | $101 |
| Insulin Aspart Flexpen | 22 | $6,909 | $314 |
| Levothyroxine | 314 | $6,190 | $20 |
| Comfort Ez Pen Needle | 28 | $6,143 | $219 |
| Admelog Solostar | 15 | $4,896 | $326 |
| Ultra-Fine Nano Pen Needle | 40 | $4,040 | $101 |
| Tirosint | 16 | $3,985 | $249 |
| Metformin | 394 | $3,253 | $8 |
| Atorvastatin | 276 | $2,952 | $11 |
| Pioglitazone | 174 | $2,609 | $15 |
| Ezetimibe | 81 | $2,311 | $29 |
| Metformin Hcl Er | 167 | $2,299 | $14 |
| Synthroid | 21 | $1,567 | $75 |
| Losartan | 136 | $1,479 | $11 |
| Rosuvastatin | 57 | $1,279 | $22 |
| Hydrocortisone | 23 | $1,167 | $51 |
| Ulticare Pen Needle | 14 | $1,013 | $72 |
| Methimazole | 90 | $890 | $10 |
| Lantus | 13 | $870 | $67 |
| Gabapentin | 17 | $604 | $36 |
| Lisinopril | 68 | $559 | $8 |
| Alcohol Pads | 11 | $548 | $50 |
| Amlodipine Besylate | 98 | $541 | $6 |
| Alendronate | 60 | $536 | $9 |
| Valsartan | 11 | $406 | $37 |
| Glipizide | 39 | $352 | $9 |
| Simvastatin | 32 | $276 | $9 |
| Benazepril | 15 | $144 | $10 |
| Glimepiride | 11 | $97 | $9 |
| Hydrochlorothiazide | 17 | $75 | $4 |
| Dexamethasone | 20 | $12 | $1 |
Year by year
| 2024 | 5,806 | 541 | 0% (0) | 51% | $2,993,393 |
| 2023 | 3,603 | 425 | 0% (0) | 50% | $2,284,530 |
| 2022 | 64 | 39 | 0% (0) | None | $38,535 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 47 drugs
| Ozempic | 245 | $429,930 | $1,755 |
| Jardiance | 307 | $366,634 | $1,194 |
| Trulicity | 211 | $358,963 | $1,701 |
| Farxiga | 133 | $183,382 | $1,379 |
| Rybelsus | 79 | $135,562 | $1,716 |
| Novolog Flexpen | 77 | $94,046 | $1,221 |
| Humalog Kwikpen U-100 | 64 | $67,800 | $1,059 |
| Januvia | 44 | $54,808 | $1,246 |
| Mounjaro | 24 | $47,009 | $1,959 |
| Tradjenta | 30 | $46,783 | $1,559 |
| Lantus Solostar | 69 | $35,882 | $520 |
| Gvoke Hypopen 2-Pack | 48 | $33,093 | $689 |
| Vascepa | 41 | $28,773 | $702 |
| Invokana | 24 | $28,179 | $1,174 |
| Kerendia | 27 | $26,127 | $968 |
| Tresiba Flextouch U-100 | 42 | $22,845 | $544 |
| Toujeo Solostar | 37 | $19,660 | $531 |
| Basaglar Kwikpen U-100 | 41 | $16,765 | $409 |
| Repaglinide | 187 | $15,624 | $84 |
| Icosapent Ethyl | 22 | $14,913 | $678 |
| Cinacalcet | 12 | $11,466 | $956 |
| Nateglinide | 38 | $7,690 | $202 |
| Nano 2nd Gen Pen Needle | 45 | $7,384 | $164 |
| Insulin Lispro Kwikpen U-100 | 21 | $6,310 | $300 |
| Levothyroxine | 209 | $5,968 | $29 |
| Atorvastatin | 186 | $5,008 | $27 |
| Metformin | 248 | $4,948 | $20 |
| Pioglitazone | 116 | $3,960 | $34 |
| Livalo | 11 | $3,381 | $307 |
| Ezetimibe | 38 | $2,977 | $78 |
| Ultra-Fine Nano Pen Needle | 24 | $2,795 | $116 |
| Comfort Ez Pen Needle | 12 | $2,666 | $222 |
| Rosuvastatin | 60 | $2,583 | $43 |
| Metformin Hcl Er | 88 | $2,303 | $26 |
| Ulticare Pen Needle | 25 | $2,157 | $86 |
| Losartan | 85 | $1,706 | $20 |
| Methimazole | 53 | $1,272 | $24 |
| Alendronate | 50 | $1,038 | $21 |
| Amlodipine Besylate | 60 | $1,032 | $17 |
| Gabapentin | 15 | $510 | $34 |
| Lisinopril | 27 | $486 | $18 |
| Simvastatin | 32 | $408 | $13 |
| Ultracare Pen Needle | 13 | $368 | $28 |
| Glipizide | 28 | $274 | $10 |
| Hydrochlorothiazide | 16 | $202 | $13 |
| Metoprolol | 12 | $108 | $9 |
| Dexamethasone | 27 | $21 | $1 |
Money from drug and device companies
$1,078 in 2025
| 2025 | 20 | 46 | None | $1,078 |
| 2024 | 26 | 141 | None | $3,600 |
| 2023 | 24 | 146 | None | $3,246 |
| 2022 | 18 | 38 | None | $1,246 |
| 2021 | 4 | 5 | None | $96 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | Ozempic | $225 | 11 payments
|
| Aurinia Pharma U.S. | Lupkynis | $87 | 4 payments
|
| Amgen | Evenity | $83 | 3 payments
|
| Lilly USA | Taltz | $81 | 3 payments
|
| Corcept Therapeutics | Korlym | $72 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $63 | 2 payments
|
See all 46 published payments
| Amgen | Meals · 2025-12-16 | Evenity | $29 |
| Tandem Diabetes Care | Meals · 2025-11-11 | T:Slim X2 Insulin Pump With Control-Iq | $28 |
| Amgen | Meals · 2025-08-19 | Evenity | $37 |
| Dexcom | Meals · 2025-05-10 | Dexcom G6 Transmitter | $22 |
| Novo Nordisk | Meals · 2025-05-09 | Ozempic | $12 |
| Aurinia Pharma U.S. | Meals · 2025-05-06 | Lupkynis | $26 |
| Novo Nordisk | Meals · 2025-05-05 | Rybelsus | $20 |
| Abbvie | Meals · 2025-04-29 | Synthroid | $15 |
| Novo Nordisk | Meals · 2025-04-24 | Ozempic | $25 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-24 | Kerendia | $16 |
| Aurinia Pharma U.S. | Meals · 2025-04-24 | Lupkynis | $17 |
| Pfizer | Meals · 2025-04-23 | Prevnar 20 | $26 |
| Recordati Rare Diseases Inc. | Meals · 2025-04-18 | Isturisa | $18 |
| Xeris Pharmaceuticals | Meals · 2025-04-18 | Recorlev | $21 |
| Novo Nordisk | Meals · 2025-04-16 | Ozempic | $23 |
| Neurocrine BioSciences | Meals · 2025-04-15 | Crenessity | $24 |
| Novo Nordisk | Meals · 2025-04-11 | Ozempic | $21 |
| Lilly USA | Meals · 2025-04-09 | Taltz | $28 |
| Abbott Laboratories | Meals · 2025-04-02 | Freestyle Libre 3 | $22 |
| Novo Nordisk | Meals · 2025-03-31 | Ozempic | $24 |
| Corcept Therapeutics | Meals · 2025-03-30 | Korlym | $72 |
| Recordati Rare Diseases Inc. | Meals · 2025-03-26 | Isturisa | $19 |
| Lilly USA | Meals · 2025-03-25 | Mounjaro | $21 |
| Novo Nordisk | Meals · 2025-03-25 | Ozempic | $17 |
| Ascendis Pharma Endocrinology | Meals · 2025-03-19 | Yorvipath | $16 |
| Novo Nordisk | Meals · 2025-03-11 | Ozempic | $19 |
| Xeris Pharmaceuticals | Meals · 2025-03-07 | Recorlev | $21 |
| Sanofi Pasteur | Meals · 2025-03-05 | None | $30 |
| Mannkind | Meals · 2025-02-27 | Afrezza | $19 |
| Aurinia Pharma U.S. | Meals · 2025-02-25 | Lupkynis | $25 |
| Sanofi-Aventis U.S. | Meals · 2025-02-19 | Tzield | $16 |
| Tandem Diabetes Care | Meals · 2025-02-19 | T:Slim X2 Insulin Pump With Control-Iq | $35 |
| Novo Nordisk | Meals · 2025-02-18 | Ozempic | $25 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-14 | Kerendia | $23 |
| Novo Nordisk | Meals · 2025-02-13 | Ozempic | $14 |
| Abbott Laboratories | Meals · 2025-02-07 | Freestyle Libre 3 | $20 |
| Lilly USA | Meals · 2025-02-06 | Taltz | $32 |
| Ascendis Pharma Endocrinology | Meals · 2025-02-05 | Yorvipath | $22 |
| Ascensia Diabetes Care Us | Meals · 2025-02-01 | None | $24 |
| Kyowa Kirin | Meals · 2025-01-29 | Crysvita | $26 |
| Amgen | Meals · 2025-01-28 | Tepezza | $17 |
| Recordati Rare Diseases Inc. | Meals · 2025-01-21 | Isturisa | $21 |
| Dexcom | Meals · 2025-01-17 | Dexcom G6 Transmitter | $22 |
| Mannkind | Meals · 2025-01-10 | Afrezza | $24 |
| Novo Nordisk | Meals · 2025-01-08 | Ozempic | $25 |
| Aurinia Pharma U.S. | Meals · 2025-01-07 | Lupkynis | $19 |
See earlier years (2024, 2023, 2022, 2021)
2024: $3,600
| Xeris Pharmaceuticals | Recorlev | $609 | 14 payments
|
| Lilly USA | Mounjaro | $452 | 18 payments
|
| Novo Nordisk | Ozempic | $432 | 22 payments
|
| IBSA Pharma | Tirosint | $335 | 6 payments
|
| Corcept Therapeutics | Korlym | $199 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $166 | 11 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $148 | 11 payments
|
| Mannkind | Afrezza | $147 | 7 payments
|
| Recordati Rare Diseases Inc. | Signifor Lar | $128 | 6 payments
|
| Pfizer | Prevnar 20 | $121 | 5 payments
|
| Ascensia Diabetes Care Us | Eversense E3 Sensor Kit - Retail | $119 | 5 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $106 | 5 payments
|
| Amgen | Tepezza | $87 | 4 payments
|
| Sanofi-Aventis U.S. | Tzield | $84 | 5 payments
|
| Aurinia Pharma U.S. | Lupkynis | $73 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $65 | 2 payments
|
| Radius Health | None | $60 | 3 payments
|
| Verity Pharmaceuticals | Tlando | $49 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $45 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $37 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $32 | 1 payment
|
| Sanofi Pasteur | Fluzone High-Dose | $25 | 1 payment
|
| Sobi | Kineret | $25 | 1 payment
|
| Esperion Therapeutics | Nexletol | $24 | 1 payment
|
| Madrigal Pharmaceuticals | Resmetirom | $19 | 1 payment
|
| Antares Pharma | Xyosted | $13 | 1 payment
|
2023: $3,246
| Lilly USA | Trulicity | $485 | 22 payments
|
| Novo Nordisk | Ozempic | $472 | 31 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $267 | 10 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $244 | 6 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $244 | 13 payments
|
| IBSA Pharma | Tirosint | $230 | 6 payments
|
| MannKind | Afrezza | $226 | 17 payments
|
| Ascensia Diabetes Care Us | None | $194 | 5 payments
|
| Radius Health | Tymlos | $190 | 10 payments
|
| Horizon Therapeutics plc | Tepezza | $176 | 4 payments
|
| Corcept Therapeutics | Korlym | $118 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $66 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $57 | 3 payments
|
| Ascendis Pharma | None | $50 | 3 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $33 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $27 | 1 payment
|
| CeQur | Cequr Simplicity | $26 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $25 | 1 payment
|
| Embecta | Bd Nano 2nd Gen Pen Needle | $25 | 1 payment
|
| Kyowa Kirin | Crysvita | $20 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $19 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $19 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $19 | 1 payment
|
| Ucb | Cimzia | $15 | 1 payment
|
2022: $1,246
| Lilly USA | Retevmo | $408 | 5 payments
|
| Novo Nordisk | Rybelsus | $249 | 9 payments
|
| Corcept Therapeutics | Korlym | $116 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $84 | 4 payments
|
| Radius Health | Tymlos | $70 | 3 payments
|
| Dexcom | Dexcom G6 Transmitter | $40 | 2 payments
|
| Mannkind | Afrezza | $39 | 2 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $34 | 2 payments
|
| Amryt Pharma Holdings | Mycapssa | $30 | 1 payment
|
| Aurinia Pharma U.S. | Lupkynis | $28 | 1 payment
|
| Abbvie | Ubrelvy | $24 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $21 | 1 payment
|
| Amgen | Enbrel | $21 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $20 | 1 payment
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $17 | 1 payment
|
| TOLMAR Pharmaceuticals | Fensolvi | $15 | 1 payment
|
| Sanofi-Aventis U.S. | Toujeo | $14 | 1 payment
|
2021: $96
| AbbVie | Creon | $36 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $21 | 1 payment
|
| Alkermes | Vivitrol | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $19 | 1 payment
|
Professional record
- NPI
- 1629670914
- Licence
- CA 58830
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, medical (363AM0700X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2020-11-11
- NPI last updated
- 2025-12-23
- NPI record certified
- 2025-12-23
This is when the NPI record was last certified, not a medical board exam.